Applicant, as named in the Orange Book
Knoa Pharma
Next listed expiry: Oxycontin on 24 Aug 2027. 3 products with live protection, 2 without.
Products with listed protection
| Drug | Ingredient | NDA | Earliest generic entry | Basis |
|---|
| Oxycontin · 7 strengths oxycodone hydrochloride | oxycodone hydrochloride | 022272 | 24 Aug 2027 | patent |
| Hysingla Er · 6 strengths hydrocodone bitartrate | hydrocodone bitartrate | 206627 | 21 Dec 2031 | patent |
| Zurnai (Autoinjector) nalmefene hydrochloride | nalmefene hydrochloride | 218590 | 5 Nov 2039 | patent |
Recent events
- 24 Oct 2026Oxycontin · Enters 12-month window basis: patent24 Aug 2027
- 24 Oct 2026Oxycontin · Enters 12-month window basis: patent24 Aug 2027
- 24 Oct 2026Oxycontin · Enters 12-month window basis: patent24 Aug 2027
Products without listed protection (2)
| Drug | Ingredient | NDA | Earliest generic entry | Basis |
|---|
| Butrans · 5 strengths buprenorphine | buprenorphine | 021306 | open now | no listed protection |
| Ms Contin · 3 strengths morphine sulfate | morphine sulfate | 019516 | open now | no listed protection |